Changes in depression symptom profile with gender-affirming hormone use in transgender persons 79 Table 3.1. Clinical and demographic baseline characteristics of study participants. Transmasculine group Transfeminine group Sample size in total cohort 110 89 Age Median (IQR) 22 (20 to 26) 26 (23 to 33) Gender identity (n, %) Binary* 77 (70.0%) 70 (78.6%) Non-binary * 19 (17.3%) 5 (5.6%) Don’t know 1 (0.9%) 0 (0%) Missing 13 (11.8%) 14 (15.7%) Current or lifetime MINI+ psychiatric diagnoses (n, %) Any comorbidity 55 (50.0%) 49 (55.1%) Depression or dysthymia 52 (47.3%) 42 (47.2%) Generalized Anxiety Disorder 4 (3.6%) 2 (2.2%) Social phobia or agoraphobia 13 (11.8%) 12 (13.5%) Posttraumatic Stress Disorder 5 (4.5%) 1 (1.1%) ADHD 4 (3.6%) 3 (3.4%) Missing** 27 (24.5%) 16 (18.0%) Alcohol (median, interquartile range) Consumptions per week 0.25 (0 to 1) 0.4 (0 to 2) Missing 17 (15.5%) 15 (16.9%) Drug use (n, %) No drug use 96 (87.3%) 76 (85.4%) Drug use 11 (10.0%) 5 (5.6%) Missing 3 (2.7%) 8 (9.0%) Smoking (n, %) Never 75 (68.2%) 63 (70.8%) Previous 14 (12.7%) 6 (6.7%) Current 16 (14.5%) 13 (14.6%) Missing 5 (4.5%) 9 (10.1%) Psychotropic medication use (n, %) Any psychotropic medication 16 (14.5%) 10 (11.2%) Antidepressants 9 (8.2%) 5 (5.6%) Anxiolytics 3 (2.7%) 0 (0%) Stimulants 4 (3.6%) 6 (6.7%) Antipsychotics 4 (3.6%) 2 (2.2%) Mood stabilizers 1 (0.9%) 0 (0%) Form of testosterone prescribed at start of GAHT (n, %) Testosterone gel 92 (83.6%) - Testosterone esters 16 (14.5%) - Testosterone undecanoate 2 (1.8%) - Form of estrogen prescribed at start of GAHT (n, %) Estradiol tablets - 49 (55.0%) Estradiol patches - 28 (31.5%) Estradiol gel - 6 (6.7%) Estradiol spray - 3 (3.4%) None*** - 3 (3.4%) Form of anti-androgens prescribed at start of GAHT (n, %) Cyproterone acetate - 17 (19.1%) GnRH analogues - 67 (75.3%) None*** - 5 (5.6%) * Binary gender identity: identification as (transgender) man or woman; all participants who did not identify with these gender identities were grouped under non-binary gender identity. ** Missing MINI+ since the MINI+ interview was not conducted. *** Use of only estrogen or anti-androgens was categorized as incomplete GAHT use and studied in a sensitivity analysis. Of all participants, 73.9% of the participants reported a binary gender identity (i.e. (transgender) man or (transgender) woman), 12.1% reported a
RkJQdWJsaXNoZXIy MTk4NDMw